anlotinib + tegafur + gimeracil + oteracil

Anlotinib + tegafur + gimeracil + oteracil is a combination therapy being investigated for the treatment of advanced pancreatic cancer. Anlotinib is a small-molecule multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor angiogenesis and proliferation by inhibiting VEGFR1/2/3, FGFR1-4, PDGFRα/β, and c-Kit. The other components—tegafur, gimeracil, and oteracil—constitute the oral fluoropyrimidine S-1. Tegafur is a prodrug of 5-fluorouracil (5-FU); gimeracil inhibits dihydropyrimidine dehydrogenase (DPD) to prevent the degradation of 5-FU; and oteracil inhibits orotate phosphoribosyltransferase (OPRT) to reduce 5-FU-induced gastrointestinal toxicity. This combination aims to provide synergistic antitumor activity by combining anti-angiogenic effects with potent, well-tolerated chemotherapy. It is primarily being developed by the Cancer Hospital Affiliated to Guangxi Medical University for patients who have failed first-line chemotherapy.

Brand names

Focus V

Other names

Anlotinib plus S-1Anlotinib + S-1